EP3530278A4 - Zusammensetzung mit protein-phosphatase-1-hemmendem peptid zur behandlung von gefässerkrankungen - Google Patents

Zusammensetzung mit protein-phosphatase-1-hemmendem peptid zur behandlung von gefässerkrankungen Download PDF

Info

Publication number
EP3530278A4
EP3530278A4 EP17863591.8A EP17863591A EP3530278A4 EP 3530278 A4 EP3530278 A4 EP 3530278A4 EP 17863591 A EP17863591 A EP 17863591A EP 3530278 A4 EP3530278 A4 EP 3530278A4
Authority
EP
European Patent Office
Prior art keywords
treatment
composition
vascular diseases
protein phosphatase
inhibitory peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17863591.8A
Other languages
English (en)
French (fr)
Other versions
EP3530278A2 (de
Inventor
Woo Jin Park
Seung Pil Jang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bethphagen Inc
Original Assignee
Gwangju Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwangju Institute of Science and Technology filed Critical Gwangju Institute of Science and Technology
Publication of EP3530278A2 publication Critical patent/EP3530278A2/de
Publication of EP3530278A4 publication Critical patent/EP3530278A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17863591.8A 2016-10-24 2017-10-24 Zusammensetzung mit protein-phosphatase-1-hemmendem peptid zur behandlung von gefässerkrankungen Withdrawn EP3530278A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160138612 2016-10-24
PCT/KR2017/011796 WO2018080146A2 (ko) 2016-10-24 2017-10-24 단백질 탈 인산화 효소 1 억제 펩타이드를 포함하는 혈관 질환 치료용 조성물

Publications (2)

Publication Number Publication Date
EP3530278A2 EP3530278A2 (de) 2019-08-28
EP3530278A4 true EP3530278A4 (de) 2019-10-30

Family

ID=62023742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17863591.8A Withdrawn EP3530278A4 (de) 2016-10-24 2017-10-24 Zusammensetzung mit protein-phosphatase-1-hemmendem peptid zur behandlung von gefässerkrankungen

Country Status (6)

Country Link
US (1) US11426441B2 (de)
EP (1) EP3530278A4 (de)
JP (1) JP6910700B2 (de)
KR (1) KR102077333B1 (de)
CN (1) CN109890400B (de)
WO (1) WO2018080146A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824758B (zh) * 2019-02-27 2022-04-22 中山大学 抑制一氧化氮合酶降解和高血压的多肽及其应用
CN111154742B (zh) * 2020-02-07 2021-05-25 青岛农业大学 一种受丹参调节的血管壁修复相关的蛋白肽
JP7490286B2 (ja) * 2021-02-25 2024-05-27 ルーマス リミテッド 矩形導波路を有する光学アパーチャ増倍器
WO2024253408A1 (ko) * 2023-06-05 2024-12-12 (주)벳바젠 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용 데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025804A2 (en) * 1998-11-02 2000-05-11 The Regents Of The University Of California A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
US20040214760A1 (en) * 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002317093A1 (en) 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
US20180099029A9 (en) * 2010-04-15 2018-04-12 Mount Sinai School Of Medicine Serca2 therapeutic compositions and methods of use
CA2914029A1 (en) * 2013-06-07 2014-12-11 The Regents Of The University Of California Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
KR101751329B1 (ko) 2015-05-26 2017-06-27 주식회사 인세라 세라믹 구형 비드의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025804A2 (en) * 1998-11-02 2000-05-11 The Regents Of The University Of California A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
US20040214760A1 (en) * 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018080146A2 *
SEUNG PIL JANG ET AL: "A Decoy Peptide Targeted to Protein Phosphatase 1 Attenuates Degradation of SERCA2a in Vascular Smooth Muscle Cells", PLOS ONE, vol. 11, no. 10, 28 October 2016 (2016-10-28), pages 1 - 14, XP055537528, DOI: 10.1371/journal.pone.0165569 *

Also Published As

Publication number Publication date
US11426441B2 (en) 2022-08-30
KR20180044829A (ko) 2018-05-03
CN109890400B (zh) 2022-12-20
EP3530278A2 (de) 2019-08-28
JP6910700B2 (ja) 2021-07-28
WO2018080146A3 (ko) 2018-08-09
KR102077333B1 (ko) 2020-02-13
WO2018080146A2 (ko) 2018-05-03
US20190328823A1 (en) 2019-10-31
JP2020500166A (ja) 2020-01-09
CN109890400A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
EP3448875A4 (de) Zusammensetzungen zur behandlung einer erkrankung
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3866781A4 (de) Neuartige zusammensetzung zur behandlung von entzündlichen erkrankungen
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
EP3463341A4 (de) Aminoacylindol-immunmodulatoren zur behandlung von autoimmunerkrankungen
EP3890725A4 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EP3496662A4 (de) Aus seide gewonnenes protein zur behandlung von entzündungen
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP3661553A4 (de) Verfahren und zusammensetzungen zur behandlung von amyloidablagerungskrankheiten
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3523281A4 (de) Aktivatoren von autophagischem fluss und phospholipase d und reinigung von proteinaggregaten einschliesslich tau und behandlung von proteinopathien
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
EP3288565A4 (de) Extrazelluläre matrixzusammensetzungen zur behandlung von krebs oder immunkrankheiten
EP3766497A4 (de) Arzneimittel zur behandlung von husten
EP3539550A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von neurodegenerativen erkrankungen mit blütenextrakt von fliederseidelbast oder fraktionen davon als wirkstoff
EP3773629A4 (de) Car-treg-basierte therapien zur behandlung von neurodegenerativen erkrankungen
EP3866777A4 (de) Kombinationstherapien zur behandlung von entzündlichen erkrankungen
EP3316887A4 (de) Gls1-hemmer zu behandlung von erkrankungen
EP3805216A4 (de) Verbindungen zur behandlung oder vorbeugung von lebererkrankungen
EP3530278A4 (de) Zusammensetzung mit protein-phosphatase-1-hemmendem peptid zur behandlung von gefässerkrankungen
EP3413898A4 (de) Verwendung von trehalose zur behandlung von neurologischen erkrankungen
EP3634394A4 (de) Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190513

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20191002

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/18 20160101ALI20190926BHEP

Ipc: A61K 38/08 20190101AFI20190926BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BETHPHAGEN INC.

111L Licence recorded

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Free format text: EXCLUSIVE LICENSE

Name of requester: NADIANBIO LTD., KR

Effective date: 20200515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240125

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240710

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241112